Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Diabetes startup brews up $11M after 'serendipitous spill' led to creation of new CGM tech
https://www.fiercebiotech.com/medtech/hagar-brews-up-11m-after-a-serendipitous-spill-led-to-creation-new-cgm-tech
Perhaps aiming to join their ranks is Israeli startup Hagar, with its GWave technology that measures blood sugar levels using noninvasive radio waves rather than an implanted sensor or repeated fingersticks.
According to Hagar lore, the technology came about after Geri Waintraub, the company’s co-founder and chief technology officer, accidentally spilled a cup of tea on a radio frequency device during a separate research project and concluded that the ensuing reaction was caused by the sugar in his tea. Thus, GWave was born.
The first generation of the GWave sensor is a device about a third the size of a standard smartphone, inserted into a ceramic bracelet. It uses Bluetooth to transmit its glucose readings to an accompanying mobile app that tracks readings and alerts users to fluctuations in their blood sugar levels.
While radio waves are a form of electromagnetic radiation, GWave produces “significantly less” amounts than a smartphone, according to Hagar.
A proof-of-concept study found the company's radio frequency technology was able to continuously measure glucose levels with at least 90% accuracy, compared to the estimated 70% rate for traditional continuous glucose monitors.
According to the company, that difference stems from the fact that Hagar’s system directly measures glucose in the blood in real time. Other CGMs may use a sensor implanted under the skin to take measurements from the interstitial fluid between cells and may often have to be calibrated throughout the day with routine fingerstick blood tests.
Fitbit CEO and co-founder James Park on his own fitness routine and selling to Google for $2.1 billion
https://www.cnbc.com/amp/2021/08/03/fitbit-ceo-james-park-on-habits-achieving-success-and-sale-to-google.html
Apple Watch 'black box' algorithms unreliable for medical research
https://appleinsider.com/articles/21/07/27/apple-watch-black-box-algorithms-unreliable-for-medical-research/amp/
Apple's use of algorithms to analyze data may be an issue for medical research, after a Harvard professor discovered inconsistencies in data from one Apple Watch accessed at different times.
One of the benefits of mobile devices and wearable devices like the Apple Watch is that improvements can be made in software. In medical research, this may not necessarily be a good thing, and has prompted one study to rethink its methodology.
According to JP Onnela, an associate professor of biostatistics at the Harvard T.H. Chan School of Public Health, these changes can produce inconsistencies in data collection. This can even be the case for analyzing the same data, but at different moments in time.
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
https://www.drugdeliverybusiness.com/dexcom-ceo-kevin-sayer-says-g7-will-be-wonderful/
As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring.
No, the next Apple Watch won't measure blood glucose and alcohol
https://www.techradar.com/amp/news/no-the-next-apple-watch-wont-measure-blood-glucose-and-alcohol
How does the 'wearable lab' work?
Whereas current smartwatches shine a broad-spectrum LED onto your skin and analyzing changes in the light that's reflected back, Rockley's sensor module uses many discrete laser outputs from a single chip. Put simply, this means it can identify and assess many more biometric markers, including the properties of blood, interstitial fluids, and different layers of the skin.
We'll need to be patient, though. Rockley has said that it's targeting the consumer electronics market, but we very much doubt its new tech will be appearing in Apple Watches any time soon.
For starters, the sensor stack would need approval from the FDA and other public health bodies before they could be used in a commercially available watch, and so far the system is nowhere near that stage. Rockley is planning to begin its own in-house human studies over the coming months, so it'll be a long time before the wearable lab is ready for the big time.
Things are also complicated on the software and processing side. Rockley's system relies heavily on cloud computing, and transfers data to custom, cloud-based analytics engines via a smartphone app. This is sensitive medical information, so Apple would need to ensure that it was fully protected in compliance with GDPR and other data protection laws in all the countries where it operates.
The servers would also need to be able to cope with and process the enormous volume of data generated by millions of users.
Rockley Photonics, an Apple supplier, has today unveiled an advanced digital sensor system that is likely to come to the Apple Watch to enable a wide range of new health tracking features.
https://www.macrumors.com/2021/07/14/apple-supplier-unveils-health-tracking-tech/amp/
Demand is growing for continuous glucose monitoring for type 2 diabetes. Primary care doctors need to prepare
https://www.statnews.com/2021/06/30/continuous-glucose-monitoring-type-2-diabetes-primary-care/
Fitbit co-founder: ‘We lead and others follow’ – here's where Fitbit's heading next
https://www.wareable.com/fitbit/eric-friedman-interview-1
And even as the company’s hardware numbers are eclipsed by huge competitors, Friedman says that Fitbit is still a leader – and others copy.
“There's a quote that imitation is the sincerest form of flattery. The competition has been flattering the heck out of Fitbit for the last several years. We recognise that people are looking to us for thought leadership, but then quickly copy us,” Friedman said.
And Friedman says that even Apple, which has come to dominate the smartwatch market, followed Fitbit’s lead:
“When smartwatches first came onto the scene, most of them took a phone and put it on the wrist. It took a couple years, but everyone from Apple to Samsung went, 'oh actually Fitbit on this health and wellness thing, they've got something,'" he said.
“They radically pivoted and have been following us. We take it as a compliment.”
This week we’ve seen a new Fitbit patent for a smart ring that would use a different types of heart rate and blood oxygen detection than we’ve seen on Fitbit’s wrist wearables. And the company has already stated its interest in launching blood pressure and glucose monitoring features.
“A lot of very smart researchers have looked at things like pulse arrival time, pulse wave velocity, a number of those metrics, trying to tie it back to blood pressure. There's often been smoke, but no one's actually found the fire.”
“We're working on our own kind of approaches,” Friedman said.
Fitbit smart ring patent reveals medical grade SpO2 and blood pressure tracking
https://www.wareable.com/fitbit/fitbit-smart-ring-patent-8486
And the wording indicates that Fitbit believes that transmissive detection could be the key to tracking future data points, such as cuffless blood pressure and even glucose levels.
The patent states that: “Systems can utilize the ring to monitor the oxygen saturation, pulse, blood pressure, glucose levels and lipd concentration” of the wearer.
Visualizing the Future of Technology With Ron Erickson
https://www.huffpost.com/entry/ron-erickson_b_4252114
Ron made this statement in 2014.
"Everything in the world has a unique machine readable chromatic or color identifier. With our ChromaID technology we can read that unique identifier. I think ChromaID technology will, within a decade, be embedded in everyday devices and become a part of our daily lives."
https://en.wikipedia.org/wiki/Ron_Erickson_(investor)
Dexcom’s CEO claims company has a ‘compelling’ case for broader CGM use
In a wide-ranging interview, Dexcom’s CEO shared more about the company’s push to prove its continuous glucose monitor can be used both for patients with Type 1 and Type 2 diabetes, and how the device-maker is handling a growing number of competitors.
https://medcitynews.com/2021/06/dexcoms-ceo-claims-company-has-a-compelling-case-for-broader-cgm-use/
Cramer’s lightning round: Senseonics Holdings is too speculative
https://www.cnbc.com/2021/06/17/cramers-lightning-round-senseonics-holdings-is-too-speculative-.html
Senseonics Holdings: “That competes against Dexcom and competes against Abbott, which are big competitors, so it’s just a speculative one.”
Apple Plans Faster Watch, Future Temperature and Glucose Sensors
https://www.bloomberg.com/news/articles/2021-06-14/apple-plans-faster-watch-future-temperature-and-glucose-sensors?sref=ExbtjcSG
Apple had previously aimed to put a body temperature sensor in this year’s model, but that is now more likely to be included in the 2022 update. The blood-sugar sensor, which would help diabetics monitor their glucose levels, is unlikely to be ready for commercial launch for several more years.
Blood sugar monitoring has been long in the works at Apple and would be a feature thus far unrivaled by competitors. Apple and others currently rely on apps that let users input their glucose levels manually, while medical device companies like Dexcom Inc. offer blood sugar monitors that share data with the Apple Watch. Users typically need to prick their finger to draw blood for an accurate glucose test, but Apple is aiming for a non-invasive solution that can analyze blood through the skin.
Wearables and health tracking: photonics could reinvent the Apple Watch
https://www.medicaldevice-network.com/analysis/apple-watch-photonics/
Last year, high-tech medical device company Indigo Diabetes raised €38m in a Series B financing round to support the development of its ‘invisible’ continuous glucose monitoring device for diabetes. The company has developed a small chip that uses nanophotonics to measure glucose and ketones in diabetes patients and is designed to be inserted subcutaneously in a patient’s skin. The first clinical trial into its sensor technology began in March this year.
The results of Indigo’s trial could shed some light on how well Rockley’s photonics technology product might work, even embedded inside an Apple Watch instead of under the skin.
For What It's Worth
D L Carlson Investment Group Inc. took a 10,000 shares position in Know Labs, Inc.
https://fintel.io/so/us/knwn
https://whalewisdom.com/filer/d-l-carlson-investment-group-inc#tabholdings_tab_link
http://carlsoninvest.com/
From Know, Labs 10Q Filing
For the quarterly period ended March 31, 2021
https://sec.report/Document/0001654954-21-005292/
The CEO was payed a bonus and employment has increased to 10 employees at Know, Labs.
On March 18, 2021, the Company approved a $250,000 bonus for Mr. Bosua.
As of March 31, 2021, we had 10 full-time employees.
The Holy Grail of health tracking
https://www.tomsguide.com/amp/news/apple-watch-7-killer-upgrade-teased-in-new-survey
Blood glucose tracking has been a target for Apple for years, and CEO Tim Cook was even seen wearing what appeared to be a prototype device way back in 2017.
The long road to it becoming a feature is a reflection of both how difficult the challenge is, and the importance of getting it right. While blood sugar levels are a useful metric for people looking to lose weight, for diabetics the knowledge is of paramount importance, and a flakey, inaccurate sensor just wouldn’t do.
But if the implementation is done right, it could be a game changer — not least because the current medical-grade hardware is so expensive. As we explained last year, some third-party hardware is compatible with Apple Watch, but it’s extremely expensive. A continuous monitoring system such as Dexcom costs $245 for transmitters and $1,035 for a three-month supply of sensors, and even a cheaper manual system like One Drop costs between $31 and $90 a month, depending on how many daily tests you administer.
Last week, rumors of Apple’s plans became even stronger when it was revealed that the company was the biggest customer of Rockley Photonics, a U.K. business that specializes in accurate sensors for various blood signals including glucose and alcohol levels. In its SEC documents, Rockley claims that its lasers offer “up to 1,000,000 times higher resolution, 1,000 times higher accuracy and 100 times broader range in wavelengths” than existing wearable LEDs.
That all sounds very promising, but the big question is whether this implementation will make the Apple Watch 7, or whether it won't arrive until the 2022 version of the wearable. Rockley CEO Andrew Rickman said he expected the technology to be in wearables next year, which certainly makes it sound like an Apple Watch 8 thing.
But that’s not to say that Apple won’t have something in place for the Apple Watch 7. It wouldn’t be the first time the company had introduced a basic feature and then improved it over subsequent generations, after all.
Nemaura Medical Announces Order for 200,000 sugarBEAT® Sensors
https://finance.yahoo.com/news/nemaura-medical-announces-order-200-120000318.html
Based on the success of the soft launch in the U.K., the Company is advancing discussions for joint launches in Germany, Saudi Arabia and UAE
Loughborough, England, May 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced receipt of a purchase order for 5,000 sugarBEAT® transmitters and 200,000 sugarBEAT® sensors from its U.K. licensee, DB Ethitronix Ltd, with an additional rolling monthly purchase order forecast for the next 24 months of 15,000 transmitters and 2.1 million sensors, with an option to increase volumes based on customer response.
Bloomberg - Rockley Photonics Goes Public Via SPAC
https://www.bloomberg.com/news/videos/2021-05-04/rockley-photonics-goes-public-via-spac-video
Rockley Photonics to Deliver Glucose Monitoring for Apple Smartwatches
https://www.eetimes.com/rockley-photonics-to-deliver-glucose-monitoring-for-apple-smartwatches/#
Apple began purchasing products from Rockley in 2017; it is now Rockley’s largest customer with $70 million of NRE commitment to date.
He said Rockley’s technology is up to a million times more accurate than existing LEDs in high-end smartwatches today. “Smartwatches have LEDs that shine light into your skin, monitoring the scattered light that comes back to measure your pulse and, in the high-end versions, your blood oxygen. With this market taking off, it created a new opportunity for us to exploit an idea we had many years back to create a much more powerful optical sensing chip for non-invasive biomarker monitoring. The aim of Rockley was to develop a third-generation silicon photonics process that overcame the remaining hyperscale manufacturing issues and provided a wider breadth of performance capabilities compared to current processes.”
Rickman added, “We’ve shrunk a laboratory spectrometer onto a chip, creating a “clinic on a wrist.” Traditionally, when you shrink an optical instrument, the performance generally gets worse as you get less light into the device. But in this particular case, the innovative architecture we’ve designed allows our device to actually have two orders of magnitude improvement over the benchtop instrument. This is not an average spectrometer, this is a highly advanced spectrometer.”
Rockley said it has developed two products for smartwatches: a basic module and an advanced module. The basic module contains what is already seen today in a high-end smartwatch, which is blood oxygen, heart rate, and breath rate, but adds to that biomarkers that are in great demand including hydration, core body temperature, and blood pressure. Adding onto that in the advanced module, which has roughly double the number of lasers as the basic module, it has extended the infrared spectroscopy range and uses more advanced algorithms to detect alcohol, carbon monoxide, glucose indicator, and lactate.
It hopes this will set the scene for enabling continuous glucose monitoring, which it said is the holy grail of consumer wellness wearables. Other biomarkers it will be investigating in this device include albumin, urea, and creatinine, which through continuous monitoring can produce health trends and alerts for disease detection and management.
Apple Watch could gain long-sought glucose tracking with Rockley Photonics deal: report
https://www.fiercebiotech.com/medtech/apple-watch-could-gain-glucose-tracking-rockley-photonics-deal-report?mkt_tok=Mjk0LU1RRi0wNTYAAAF80hTHHNXucuIz79AOr6E5RIwzmXjUBm6mDPyio8qVwkyxvZ_znkvP1CX6qA2IEIz8lfMrE7Lw5O_Fhklhtcu0jaVuRGaDrh2w2VaqiDXVtzv71Jt1gno&mrkid=156186955
This could include long-rumored blood sugar readings, from the wrist-worn gadget, plus blood pressure measurements, hydration levels and more, following newly divulged arrangements with the sensor maker Rockley Photonics.
As first reported by The Daily Telegraph, Rockley now lists Apple as its biggest customer and contributor of the lion’s share—or potentially nearly all—of its revenues dating back to 2019.
The news comes from the company’s recent filing with the SEC after it went public earlier this year through a $1.2 billion deal with a special purpose acquisition company backed by the pan-Asia investment firm SIN Capital.
In its statement, Rockley said it expects to depend on Apple’s business for a significant portion of its income for the foreseeable future, including revenue from development and delivery of new products to the tech giant. It also expects to see its silicon photonics-powered sensor chips begin to roll out in consumer devices in late 2022.
“We expect that our immediate focus over the next two years will be on developing and commercializing our products for incorporation in consumer wearables and mobile applications, followed by medical devices in the healthcare space, and subsequently on developing our AI analytics cloud platform,” the company said, adding that while consumer wellness is its target market, it plans to file for FDA medical clearances if needed.
Rockley’s light-based sensors operate similarly to the technology already built into the underside of the Apple Watch and other fitness trackers, with more-basic hardware for measuring heartbeats, body temperature and oxygen saturation.
But the company said it is also developing an advanced sensor package to log glucose levels—and potentially provide personal alerts for high blood alcohol content, carbon monoxide poisoning, or muscle lactate levels during workouts.
Rockley Photonics Holdings Limited S-4
https://www.sec.gov/Archives/edgar/data/0001852117/000119312521105235/d144950ds4.htm
Multiple Avenues for Consistent Growth. The projected revenue growth through FY 2024 is primarily supported by the launch of wearable and mobile devices for four large consumer technology companies. The SC Health board believes there are several avenues for growth beyond consumer health that are not captured in the financial projections, including medical devices, which requires additional development efforts over the next several years including clinical trials and FDA applications and could generate more consistent and higher margin long-term revenues.
The Apple Watch may gain the ability to measure blood pressure, blood glucose, and blood alcohol levels, according to newly-revealed information about one of Apple's chosen business partners.
https://www.macrumors.com/2021/05/03/apple-watch-blood-pressure-glucose-alcohol/
Apple has been revealed to be the largest customer of the British electronics start-up Rockley Photonics, The Telegraph reports.
Rockley Photonics has developed non-invasive optical sensors for detecting multiple blood-related health metrics, including blood pressure, blood glucose, and blood alcohol levels, many of which are only normally detectable with more invasive dedicated medical equipment. Rockley's sensors beam infrared light through a user's skin, much like the existing sensors on the back of the Apple Watch for detecting heart rate and blood oxygen levels.
Rockley Photonics
Sensor maker Rockley Photonics to go public in $1.2B SPAC deal
https://www.fiercebiotech.com/medtech/sensor-maker-rockley-photonics-to-go-public-1-2b-spac-deal
Chipmaker Rockley Photonics has announced plans to go public to raise funds for its wearable sensor platform designed to continuously monitor multiple biomarkers such as blood glucose levels, hydration, blood pressure and body temperature.
Through a deal with publicly traded SC Health Corp., a blank-check special purpose acquisition company, or SPAC, Rockley will reemerge on the New York Stock Exchange under the ticker "RKLY" in a transaction listed with a pro forma enterprise value of $1.2 billion.
From connected pens to artificial pancreases: how innovative technology is transforming the diabetes treatment landscape
April 16, 2021
For example, a number of competitors have recently introduced pre-calibrated continuous glucose monitoring (CGM) devices that eliminate the need for daily finger prick calibrations.
https://clarivate.com/blog/from-connected-pens-to-artificial-pancreases-how-innovative-technology-is-transforming-the-diabetes-treatment-landscape/
Brand - UBAND CGM
Company - Know Labs Inc
Launch date - Unknown
Status - Currently undergoing development
LifePlus Announces World’s First Non-Invasive Continous Blood Glucose Monitoring Wearable
https://www.businesswire.com/news/home/20180516005422/en/LifePlus-Announces-World%E2%80%99s-Non-Invasive-Continous-Blood-Glucose
LifeLeaf by LifePlus is a multi-sensor wearable smartwatch that continuously and non-invasively monitors and tracks major chronic health risks such as diabetes, cardiac arrhythmia, congestive heart failure, COPD, sleep apnea and hypertension. It is a cloud-based AI solution with a user-interface that is simple and easy to use, as well as a connected mobile app that provides cloud-based analytics with real-time notifications. The product is targeted at the multi-billion-dollar medical wearables market, with an emphasis on the self-monitoring blood glucose market. The LifeLeaf wearable will be available later this year.
https://www.lifeplus.ai/
CAN KNOW LAB DELIVER ON THE PROMISE OF ITS “DISRUPTIVE TECHNOLOGY”?
https://www.aviseanalytics.com/can-know-lab-deliver-on-the-promise-of-its-disruptive-technology/
Particle is a disinfecting light bulb that can simultaneously illuminate and disinfect, and comes with a smart sensor. The bulb is safe for kids, pets and plants as its smart sensor deactivates UV when an individual is in the vicinity, and can be used in existing standard light sockets. The bulb’s gentle UV is 9,000x safer than traditional UV-C disinfecting products and confirms to the safety standards set by International Commission on Non-Ionizing Radiation Protection (ICNIRP) as per the Company.
The Company expects to start shipping the bulbs in the summer of 2021 and is targeting a wide array of settings such as Home, Restaurants, Hospitality, Workplaces, Schools and Universities as potential customers. Particle is also planning to offer commercial lighting options that can be customized to suit specific business requirements.
Wearable electronic skin could monitor your health
https://amp.cnn.com/cnn/2021/04/22/tech/wearable-e-skin-health-someya-spc-intl/index.html
Doctors may be just a few years away from tracking your vital signs via electronic skin worn on the body.
Researchers in Japan say they have developed an ultra-thin, lightweight e-skin that is stuck to the chest area using water spray and can be worn for a week at a time.
The technology was developed by Takao Someya, a professor at the University of Tokyo's Graduate School of Engineering. It has yet to undergo clinical trials, but Someya says he has started working with partners to develop manufacturing processes.
His latest e-skin was designed with Japan's rapidly aging population in mind. For remote health care to be most effective, Someya says it is important to monitor older people's health for long periods with high precision. Because of its durability, he says the e-skin is a powerful tool for monitoring chronic diseases like diabetes, as well as heart failure. It may also help detect early signs of illness.
FYI - South Korean chipmaker bats US FDA approval of its non-invasive glucose monitoring device
The semiconductor player claims success with D-SaLife in a recent clinical trial involving diabetic outpatients.
https://www.mobihealthnews.com/news/apac/south-korean-chipmaker-bats-us-fda-approval-its-non-invasive-glucose-monitoring-device
South Korean fabless manufacturer Dongwoon Anatech is seeking the approval of both the US and Korean Food and Drug Administration for the commercial rollout of its saliva-based glucose monitoring device after completing its first clinical trial in December.
WHAT IT DOES
The glucose monitoring device called D-SaLife, a product of six years of research and development, makes use of microcurrent control technology in determining the glucose level present in a person’s saliva sample. The meter colour codes the result of the reading which is also recorded through a mobile app.
FYI - Best glucose meter for 2021
https://www.cnet.com/google-amp/news/best-glucose-meter/
FYI -‘Noninvasive’ Glucose Monitoring for Diabetes: Where Is It Now?
https://www.healthline.com/diabetesmine/non-invasive-diabetes-technology
FYI - Dexcom G7 CGM Trial is Now Recruiting
https://diatribe.org/dexcom-g7-cgm-trial-now-recruiting
FYI - Know Labs Announces Close of Financing
$14.2 Million for Product Development, Clinical Testing and Preparation for Up List to a Major Exchange
https://www.ldmicro.com/profile/knwn/news/6029076261966372
Seattle, WA. – March 15, 2021 - OTCQB: KNWN
Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, announced today that it has closed on $14.2 million of financing. The financing was largely led by existing investors and insiders.
The financing is another step in the Company’s plans to up list on a major exchange, either NASDAQ or the NYSE, and supports continuing development and clinical testing on its platform technology with its first focus on non-invasive blood glucose monitoring, and future FDA approval. The current financing provides sufficient capital so that management can ensure product development stays on track and an up list to a major exchange is event driven rather than driven by a need for capital.
As previously stated, the Company believes an up list to a major exchange will:
Provide additional opportunities to attract institutional and retail investors, allowing the Company to broaden its investor base in the United States and internationally;
Increase the visibility of the Company, its growth strategy, accomplishments and results to date;
Enable an aggressive growth strategy;
Increase liquidity of the Company's common shares; and
Raise the Company's overall profile and ultimately enhance shareholder value.
Product development and clinical testing remain focused on:
Relationships with internationally recognized clinical research institutions to perform laboratory-based validation testing to confirm internal test results;
Continued work on miniaturization of the Know Labs platform diagnostic technology, internal testing and refinement of the use of its trade secret algorithms for exacting determination of the platform’s first use in determining blood glucose levels;
Expanding the Company’s Intellectual Property portfolio;
Preparation for submitting the Know Labs technology to the FDA for approval of its non-invasive blood glucose monitoring technology; and
Providing support to its Particle subsidiary as it launches its disinfecting light bulb into the marketplace.
FYI - 'Painless' glucose monitors are popular but little evidence they help most diabetes patients
https://www.nbcnews.com/health/diabetes/painless-glucose-monitors-are-popular-little-evidence-they-help-most-n1261013
UBAND Calorie Counter ?
https://vimeo.com/510952983
FYI - Wearable, All-in-One Health Monitor: New Skin Patch Continuously Tracks Cardiovascular Signals and Biochemical Levels
https://scitechdaily.com/wearable-all-in-one-health-monitor-new-skin-patch-continuously-tracks-cardiovascular-signals-and-biochemical-levels/#:~:text=Home%20Technology%20News-,Wearable%2C%20All%2Din%2DOne%20Health%20Monitor%3A%20New%20Skin,Cardiovascular%20Signals%20and%20Biochemical%20Levels&text=It%20is%20the%20first%20wearable,body%20at%20the%20same%20time.
Engineers at the University of California San Diego have developed a soft, stretchy skin patch that can be worn on the neck to continuously track blood pressure and heart rate while measuring the wearer’s levels of glucose as well as lactate, alcohol, or caffeine. It is the first wearable device that monitors cardiovascular signals and multiple biochemical levels in the human body at the same time.
FYI - Dexcom launches diabetes-focused venture capital fund
https://www.fiercebiotech.com/medtech/after-its-best-year-ever-dexcom-launches-diabetes-focused-venture-capital-fund
Dexcom Ventures aims to identify and invest in technologies that will support the company’s work in continuous glucose monitoring and related software applications for helping people manage their diabetes. This includes new types of blood sugar sensors, as well as broader methods of tracking a person’s metabolism.
“We strive to be value-add strategic investors by leveraging access to Dexcom’s unique industry expertise and technology leadership,” said incoming Dexcom Ventures chief Steve Pacelli, who also serves as the company’s executive VP of strategy and corporate development. The company’s initial investment in the fund was not disclosed.
“While we have matured as a company over the years, we still consider ourselves to be a ‘start-up’ of sorts,” Pacelli said. “We feel well-positioned to invest early and support our portfolio companies as they pioneer markets.”
Know Labs, Inc. Form 10-K September 30, 2020
Particle is now a direct, 100% owned subsidiary of the Company
On April 30, 2020, we approved and ratified the incorporation of Particle, Inc., a Nevada corporation. As of September 30, 2020 we are the sole shareholder but have entered into Simple Agreements for Future Equity to sell separate ownership in Particle. Particle is now a direct, 100% owned subsidiary of the Company but our future ownership could be diluted if Particle is successful in raising equity from outside investors. Particle shall utilize the same corporate offices as the Company and shall focus on the development and commercialization of our extensive intellectual property relating to electromagnetic energy
outside of the medical diagnostic arena which remains the parent company’s singular focus with its Bio-RFID technology and its initial application , the noninvasive
measurement of blood glucose.
On June 1, 2020, we approved and ratified entry into an intercompany Patent License Agreement dated May 21, 2020 with our majority owned subsidiary, Particle. Pursuant to the Agreement, Particle shall receive an exclusive non-transferrable license to use certain of our patents and trademarks, in exchange the Company shall receive: (i) a one-time fee of $250,000 upon a successful financing of Particle, and (ii) a quarterly royalty payment equal to the greater of 5% of
the Gross Sales, net of returns, from Particle or $5,000. As of September 30, 2020 Particle has not yet executed a successful financing or generated any sales.
Startup claims its new wearable can monitor blood sugar without needles
Quantum Operation Inc's prototype could be a big deal, if it works.
https://www.engadget.com/quantum-operation-inc-wearable-glucose-121015450.html
A Japanese startup at CES is claiming to have solved one of the biggest problems in medical technology: Noninvasive continuous glucose monitoring. Quantum Operation Inc, exhibiting at the virtual show, says that its prototype wearable can accurately measure blood sugar from the wrist. Looking like a knock-off Apple Watch, the prototype crams in a small spectrometer which is used to scan the blood to measure for glucose. Quantum’s pitch adds that the watch is also capable of reading other vital signs, including heart rate and ECG.
The company says that its secret sauce is in its patented spectroscopy materials which are built into the watch and its band. To use it, the wearer simply needs to slide the watch on and activate the monitoring from the menu, and after around 20 seconds, the data is displayed. Quantum says that it expects to sell its hardware to insurers and healthcare providers, as well as building a big data platform to collect and examine the vast trove of information generated by patients wearing the device.
There’s still a long way to go before we’re able to see this sort of technology in a working product, even longer before it’s in one we want to buy. But if Quantum can demonstrate that it’s avoided the pitfalls that some of its rivals have hit, and that its technology is accurate enough, this could be pretty exciting.
Of course, this being an all-virtual CES, it’s even harder to take the company’s fantastic claims at face value. If we were at the show in person, we’d be able to test the device out for ourselves and speak to the founders face-to-face. It’s worth noting, too, that there isn’t -- yet -- any peer-reviewed or otherwise externally-validated science to support this specific technology and its application. We can’t make any serious judgment on this technology yet, beyond saying that if Quantum Operation can make good on its claims, then we may be on the cusp of a very exciting time for wearables.
https://quantum-op.co.jp/